Theravance Biopharma Stock Buy Hold or Sell Recommendation
| TBPH Stock | USD 9.61 0.36 3.61% |
Given the investment horizon of 90 days and your conservative attitude towards risk, our recommendation regarding Theravance Biopharma is 'Cautious Hold'. The recommendation algorithm takes into account all of Theravance Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Theravance Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide. In addition, we conduct extensive research on individual companies such as Theravance and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Theravance |
Execute Theravance Biopharma Buy or Sell Advice
The Theravance recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Theravance Biopharma. Macroaxis does not own or have any residual interests in Theravance Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Theravance Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Theravance Biopharma Trading Alerts and Improvement Suggestions
| Theravance Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M). | |
| Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Theravance Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Theravance Biopharma to Present at Evercore HealthCONx Conference TBPH Stock News - StockTitan |
Theravance Biopharma Returns Distribution Density
The distribution of Theravance Biopharma's historical returns is an attempt to chart the uncertainty of Theravance Biopharma's future price movements. The chart of the probability distribution of Theravance Biopharma daily returns describes the distribution of returns around its average expected value. We use Theravance Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Theravance Biopharma returns is essential to provide solid investment advice for Theravance Biopharma.
| Mean Return | 0.31 | Value At Risk | -2.44 | Potential Upside | 4.50 | Standard Deviation | 2.02 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Theravance Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Theravance Stock Institutional Investors
| Shares | Pictet Asset Manangement Sa | 2024-06-30 | 878.7 K | Geode Capital Management, Llc | 2024-06-30 | 857.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 758.1 K | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 586.6 K | Bank Of America Corp | 2024-06-30 | 476.2 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 458.4 K | Northern Trust Corp | 2024-09-30 | 383.8 K | Wellington Management Company Llp | 2024-06-30 | 350.6 K | Nuveen Asset Management, Llc | 2024-06-30 | 342.7 K | Madison Avenue Partners, Lp | 2024-06-30 | 8.5 M | Weiss Asset Management Lp | 2024-06-30 | 7.5 M |
Theravance Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 1.4M | (22.5M) | (26.4M) | (8.5M) | (7.7M) | (8.1M) | |
| Change In Cash | (320.0M) | 23.4M | 8.5M | 208.2M | (258.6M) | (245.7M) | |
| Free Cash Flow | (241.4M) | (257.0M) | (211.3M) | (187.6M) | (29.5M) | (31.0M) | |
| Depreciation | 6.2M | 9.1M | 9.7M | 7.0M | 4.3M | 5.3M | |
| Other Non Cash Items | (23.0M) | (20.4M) | 3.9M | (183.3M) | 3.7M | 3.9M | |
| Capital Expenditures | 3.2M | 6.6M | 3.4M | 572K | 2.5M | 3.6M | |
| Net Income | (236.5M) | (278.0M) | (199.4M) | (92.8M) | (55.2M) | (58.0M) | |
| Investments | (84.9M) | 17.3M | 127.9M | 54.9M | 7.1M | 7.5M | |
| Net Borrowings | (2.2M) | 127.9M | (10.7M) | (631.6M) | (568.4M) | (540.0M) | |
| Change To Netincome | 60.6M | 78.3M | 21.4M | (144.5M) | (130.1M) | (123.6M) | |
| Change Receivables | (11.3M) | 6.1M | 1.8M | (2.7M) | (2.4M) | (2.3M) | |
| End Period Cash Flow | 58.9M | 82.3M | 90.8M | 299.0M | 40.4M | 38.4M |
Theravance Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Theravance Biopharma or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Theravance Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Theravance stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 1.14 | |
σ | Overall volatility | 2.09 | |
Ir | Information ratio | 0.11 |
Theravance Biopharma Volatility Alert
Theravance Biopharma has relatively low volatility with skewness of 1.4 and kurtosis of 3.81. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Theravance Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Theravance Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Theravance Biopharma Fundamentals Vs Peers
Comparing Theravance Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Theravance Biopharma's direct or indirect competition across all of the common fundamentals between Theravance Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Theravance Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Theravance Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Theravance Biopharma to competition |
| Fundamentals | Theravance Biopharma | Peer Average |
| Return On Equity | -0.23 | -0.31 |
| Return On Asset | -0.0641 | -0.14 |
| Profit Margin | (0.78) % | (1.27) % |
| Operating Margin | (0.55) % | (5.51) % |
| Current Valuation | 443.89 M | 16.62 B |
| Shares Outstanding | 49.17 M | 571.82 M |
| Shares Owned By Insiders | 5.92 % | 10.09 % |
| Shares Owned By Institutions | 96.75 % | 39.21 % |
| Number Of Shares Shorted | 4.92 M | 4.71 M |
| Price To Earning | (6.20) X | 28.72 X |
| Price To Book | 2.64 X | 9.51 X |
| Price To Sales | 7.76 X | 11.42 X |
| Revenue | 57.42 M | 9.43 B |
| Gross Profit | (12.05 M) | 27.38 B |
| EBITDA | (40.87 M) | 3.9 B |
| Net Income | (55.19 M) | 570.98 M |
| Cash And Equivalents | 132.85 M | 2.7 B |
| Cash Per Share | 1.74 X | 5.01 X |
| Total Debt | 49.16 M | 5.32 B |
| Debt To Equity | 652.20 % | 48.70 % |
| Current Ratio | 4.74 X | 2.16 X |
| Book Value Per Share | 3.79 X | 1.93 K |
| Cash Flow From Operations | (27 M) | 971.22 M |
| Short Ratio | 31.50 X | 4.00 X |
| Earnings Per Share | (1.03) X | 3.12 X |
| Price To Earnings To Growth | (0.05) X | 4.89 X |
| Target Price | 13.2 | |
| Number Of Employees | 99 | 18.84 K |
| Beta | 0.25 | -0.15 |
| Market Capitalization | 490.27 M | 19.03 B |
| Total Asset | 382 M | 29.47 B |
| Retained Earnings | (909.1 M) | 9.33 B |
| Working Capital | 108.77 M | 1.48 B |
Note: Insider Trading [view details]
Theravance Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Theravance . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Theravance Biopharma Buy or Sell Advice
When is the right time to buy or sell Theravance Biopharma? Buying financial instruments such as Theravance Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Theravance Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cigarettes Thematic Idea Now
Cigarettes
Tobacco makers and distributors across globe. The Cigarettes theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Theravance Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.